US OptionsDetailed Quotes
XBIT241220P2500
- 0.00
- 0.000.00%
15min DelayClose Nov 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV65.99%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
XBiotech Stock Discussion
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...
Where can check this information?
If I have 10 share....
Where is the money? 🧐
No comment yet